Telix to Showcase New ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline at EANM
MELBOURNE, Australia, Sept. 6, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company)today announces presentations featuring the Company's theranostic programs at the 36th Annual Congress of the European Association of Nuclear Medicine (EANM) to be held in Vienna from 9 - 13 September 2023. Further data from Telix's completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (ClinicalTrials.gov Ident...
Source: singaporestar.com